List of SGLT2 Inhibitors (2025)
List of SGLT2 Inhibitors (2025): Names, Uses & Dosing
This guide provides a complete list of SGLT2 inhibitors approved in 2025, with names, common uses, dosing, kidney (eGFR) cutoffs, and key safety considerations. Start with the quick list below, then use the table for details.
FDA‑approved SGLT2 inhibitors (A–Z):
- Bexagliflozin (Brenzavvy)
- Canagliflozin (Invokana)
- Dapagliflozin (Farxiga)
- Empagliflozin (Jardiance)
- Ertugliflozin (Steglatro)
- Sotagliflozin (Inpefa) (dual SGLT1/2 inhibitor for heart failure; not for blood‑sugar control)
SGLT2 inhibitors help the kidneys excrete excess glucose into the urine, which lowers blood sugar. Several agents in this class also provide proven heart and kidney benefits, including in some people without diabetes (Cleveland Clinic, National Kidney Foundation, StatPearls).
What are SGLT2 inhibitors?
SGLT2 inhibitors block a kidney transport protein that normally reabsorbs glucose back into the bloodstream. By inhibiting this transporter, more glucose is eliminated in urine. This lowers blood sugar and often leads to small reductions in weight and blood pressure. Importantly, several SGLT2 inhibitors also deliver heart and kidney protection.
Full list with indications and usual adult dosing
Always follow your clinician’s instructions and the official FDA label. The following table provides a detailed summary for orientation only.
Abbreviation key: CV = cardiovascular; CVD = cardiovascular disease; CKD = chronic kidney disease; HF = heart failure; ESKD = end‑stage kidney disease.
| Generic (Brand) | Key FDA‑approved adult indications | Usual adult dose |
|---|---|---|
| Bexagliflozin (Brenzavvy) | Type 2 diabetes (blood‑sugar control) | 20 mg once daily (FDA label) |
| Canagliflozin (Invokana) | Type 2 diabetes (adults and kids ≥10); lowers risk of major heart events in adults with established CVD; protects kidneys and heart in diabetic kidney disease with albuminuria | 100–300 mg once daily, before first meal (FDA label) |
| Dapagliflozin (Farxiga) | Type 2 diabetes (adults and kids ≥10); lowers risk of CV death and HF hospitalization; slows CKD progression and lowers cardiorenal risk (with or without diabetes) | 5–10 mg once daily (10 mg for HF/CKD outcomes) (FDA label) |
| Empagliflozin (Jardiance) | Type 2 diabetes (adults and kids ≥10); lowers risk of CV death, HF hospitalization, and CKD progression in adults (for some indications, with or without T2D) | 10–25 mg once daily (FDA label) |
| Ertugliflozin (Steglatro) | Type 2 diabetes (blood‑sugar control); no current FDA HF/CKD outcome indication | 5–15 mg once daily (FDA label) |
| Sotagliflozin (Inpefa) | Dual SGLT1/2. Cuts risk of CV death, HF hospital stays, and urgent HF visits in adults with HF or adults with T2D + CKD + added CV risk; not approved for blood‑sugar control | Start 200 mg once daily; may increase to 400 mg once daily as tolerated (FDA label) |
Source notes: Summaries pulled from FDA prescribing info and the clinical overview in StatPearls.
Pediatric approvals at a glance
As of 2025, three agents have U.S. pediatric indications (age ≥10) for type 2 diabetes: canagliflozin (Invokana), dapagliflozin (Farxiga), and empagliflozin (Jardiance) (canagliflozin label; dapagliflozin label; empagliflozin label).
Fixed‑dose combination examples
These combos can simplify your routine by pairing an SGLT2 with another diabetes medicine:
| Combo type | Generic components | Example Brand Name |
|---|---|---|
| SGLT2 + metformin | empagliflozin + metformin | Synjardy |
| SGLT2 + metformin | dapagliflozin + metformin | Xigduo XR |
| SGLT2 + DPP‑4 inhibitor | dapagliflozin + saxagliptin | Qtern |
| SGLT2 + DPP‑4 inhibitor | ertugliflozin + sitagliptin | Steglujan |
Source: class overview and combinations summarized in StatPearls. Always confirm with each product’s FDA label.
Safety and side effects (what to know)
Most people do well on SGLT2 inhibitors, but it’s important to understand potential risks. Talk to your clinician about your personal risk profile.
Common side effects
- More frequent urination
- Genital yeast infections
- Dizziness or lightheadedness from fluid loss
Serious risks and precautions
- Urinary tract infections (rarely can progress to kidney infection)
- Significant fluid loss and low blood pressure (higher risk with diuretics or low fluid intake)
- Diabetic ketoacidosis (including “euglycemic” DKA) with illness, prolonged fasting, heavy alcohol use, or around surgery—ask your clinician about “sick day rules” and specific instructions on when to temporarily stop your medication
- Acute kidney injury related to dehydration/volume shifts
- Very rare necrotizing fasciitis of the perineum (Fournier’s)
- For canagliflozin: the boxed warning about amputation risk was removed in 2020, but clinicians still weigh lower‑limb risk factors when choosing therapy (StatPearls).
Precautions for special populations
- Pregnancy: Generally avoid; other options are preferred in the 2nd/3rd trimesters—confirm with your clinician and the FDA label.
- Dialysis: Not recommended; see each product’s contraindications and renal guidance.
- Using insulin or a sulfonylurea: Higher risk of low blood sugar—your prescriber may lower doses of those meds.
See the FDA label for specifics and ask your prescriber what applies to you (Cleveland Clinic; FDA labels linked above).
Kidney function (eGFR) quick guide
The sugar‑lowering effect fades as eGFR drops, but heart/kidney protections may continue with some drugs. Labels set eGFR thresholds for starting or continuing—here’s a quick snapshot (confirm details in the linked labels):
- Bexagliflozin (Brenzavvy): Not recommended for glycemic control if eGFR < 30 mL/min/1.73 m² (label).
- Canagliflozin (Invokana): Not recommended for glycemic control if eGFR < 30 mL/min/1.73 m² (label).
- Dapagliflozin (Farxiga): Not recommended for glycemic control if eGFR < 45 mL/min/1.73 m²; HF/CKD indications typically use 10 mg daily per label specifics (label).
- Empagliflozin (Jardiance): Not recommended for glycemic control if eGFR < 30 mL/min/1.73 m² (label).
- Ertugliflozin (Steglatro): Not recommended if eGFR < 45 mL/min/1.73 m² (label).
- Sotagliflozin (Inpefa): Not indicated for glycemic control; follow HF labeling and your clinician’s guidance (label).
Why this matters: even if A1C effects are smaller at low eGFR, outcome benefits for the heart and kidneys can still be meaningful with certain agents (National Kidney Foundation).
Why body composition tracking can help
Some people lose a little weight on SGLT2 inhibitors. An important consideration is the composition of that weight change—whether it comes from fat mass or lean muscle. Tracking body composition can help you and your care team confirm you’re preserving lean mass while reducing fat, and spot early signs of unwanted muscle loss so you can adjust nutrition, training, or medications. If you want an objective snapshot, a short DEXA scan measures fat mass, lean mass, bone density, and visceral fat. Learn more: How a DEXA scan works and our visceral fat explainer.
Smart next steps and related resources
- Bring your latest A1C, blood pressure, and kidney labs (eGFR, uACR), plus your current med list to your appointment.
- Learn how exercise affects glucose: Does exercise lower blood sugar?
- Plan safe workouts with diabetes: Training with diabetes: safe, effective workouts
- Understand insulin resistance: Insulin resistance and weight loss
- Spot prediabetes earlier: Prediabetes symptoms and testing
Ready to get a precise baseline? Book a BodySpec DEXA scan.
Important note
This guide is for education only and not medical advice. Medication choice and dosing depend on your diagnoses, kidney function, heart status, other meds, and personal risk factors. Always confirm indications, dosing, and eGFR thresholds using the FDA label and your clinician’s recommendations.
